| [1] Chan S H,Bernard H U,Ratterree M,et al. Genomic diversity and evolution of papillomavituses in rhesus monkeys. J Virol,1997,71(7):4938-4943.
[2] 蔡红,姚堃,陈伟丽,等. 多聚酶链反应检测宫颈癌HPV感染及分型的研究. 中国病毒学,1994,9(4):291-296. Cai H,Yao K,Chen W L,et al. The research for infection and classification of cervical HPV using polymers polymerase chain reaction. Virologica Sinica,1994,9(4):291-296.
[3] 钟才高,Donald D A. HPV16及其基因诱导小鼠宫颈癌的毒理学研究. 实用预防医学,1999,6(6):401-404. Zhong C G,Donald D A. Toxicology research of cervical cancer induced by HPV16 gene in mice. Practical Preventive Medicine,1999,6(6):401-404.
[4] Lazo P A. The molecular genetics of cervical carcinoma.Br J Cancer,1999,80(12):2008-2018.
[5] Dyson N,Howley P M,Munger K,et al. The human papillomavirus 16 E7 oncoprotein is able to bind the retinoblastoma gene product. Science,1989,243(4893):934-936.
[6] Werness B A, Levine A J, Howley P M. Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science,1990,248(4951):76-79.
[7] Welter J F,Crish J F,Agarwal C,et al. Fos-related antigen (Fra-1), junB, and junD activate human involucrin promoter transcription by binding to proximal and distal AP1 sites to mediate phorbol ester effects on promoter activity. J Biol Chem,1995,270(21):12614-12622.
[8] Banks E B,Crish J F,Welter J F,et al. Characterization of human involucrin promoter distal regulatory region transcriptional activator elements——a role for Sp1 and AP1 binding sites. Biochem J, 1998,331(Pt1):61-68.
[9] James F C,Tarif M Z,Richard L E. The distal regulatory region of the human involucrin promoter is required for expression in epidermis. The Journal of Biological Chemistry,1998,273(46): 30460-30465.
[10] Parkin D M,Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine,2006,24(S3):11-25.
[11] Gargano J W,Wilkinson E J,Unger E R,et al. Prevalence of human papillomavirus types in invasive vulvar cancers and vulvar intraepithelial neoplasia 3 in the United States before vaccine introduction. J Low Genit Tract Dis,2012,16(4):471-479.
[12] Steinau M,Unger E R,Hernandez B Y,et al. Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction. J Low Genit Tract Dis,2013,17(4):397-403.
[13] Munger K,Baldwin A,Edwards K M,et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol,2004,78(21):11451-11460.
[14] Pim D,Banks L. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6. Oncogene,1999,18(52):7403-7408.
[15] Pim D,Massimi P,Banks L. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene,1997,15(3):257-264.
[16] Vonetta M W,Maria F,Valery F,et al. Human papillomavirus type 16 E6* induces oxidative stress and DNA damage. Journal of Virology,2014,88(12):6751-6761. |
